Targets › PHEX
1 program from 1 company in 1 trial: 1 Phase 2; Genitourinary; next expected readout Oct 2027.
Peptidase that cleaves SIBLING (small integrin-binding ligand, N-linked glycoprotein)-derived ASARM peptides, thus regulating their biological activity. Cleaves ASARM peptides between Ser and Glu or Asp residues. (UniProt, P78562)
Open in Phaseline: the race on PHEX, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of California, Los Angeles | Ferric Citrate Iron-based phosphate binder and iron supplement | PHEX | Phase 2 | Chronic Kidney Diseases | Oct 2027 |
Chronic Kidney Diseases (1)
small molecule (1)
University of California, Los Angeles (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.